Ninety One North America Inc. Has $6.60 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ninety One North America Inc. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 74.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,892 shares of the company's stock after buying an additional 5,063 shares during the quarter. Ninety One North America Inc.'s holdings in IDEXX Laboratories were worth $6,601,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Valley National Advisers Inc. grew its holdings in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company's stock valued at $26,000 after acquiring an additional 22 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $26,000. Geo Capital Gestora de Recursos Ltd purchased a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $28,000. Finally, Covestor Ltd grew its holdings in shares of IDEXX Laboratories by 71.8% during the 3rd quarter. Covestor Ltd now owns 67 shares of the company's stock valued at $29,000 after acquiring an additional 28 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. The Goldman Sachs Group boosted their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. boosted their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a report on Tuesday, February 6th. William Blair restated an "outperform" rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Barclays boosted their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a report on Tuesday, February 6th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Wednesday, December 20th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $591.50.

IDEXX Laboratories Stock Down 0.1 %

NASDAQ:IDXX traded down $0.45 during trading hours on Thursday, reaching $477.79. The company's stock had a trading volume of 399,635 shares, compared to its average volume of 427,362. The company has a market cap of $39.68 billion, a price-to-earnings ratio of 47.49, a price-to-earnings-growth ratio of 3.77 and a beta of 1.26. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The business's 50-day moving average is $541.86 and its 200-day moving average is $508.71. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The business's revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company's stock, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, SVP George Fennell sold 8,198 shares of the company's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company's stock, valued at $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Brian P. Mckeon sold 23,326 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares of the company's stock, valued at approximately $16,939,557.18. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock valued at $24,871,960 in the last quarter. Insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.